John Houston, Arvinas CEO

Arv­inas’ prostate can­cer treat­ment shows hints of sig­nal — but how many pa­tients will it work for?

Arv­inas re­leased in­ter­im re­sults Thurs­day morn­ing on one of its pro­tein de­grad­er drugs for prostate can­cer ahead of a fire­side chat …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.